Shares of Kenvue Inc. KVUE shed 0.14% to $21.56 Tuesday, on what proved to be an all-around favorable trading session for the ...

The stock's fall snapped a two-day winning streak.

It’s the billion dollar question. Many people eligible for hundreds of dollars in savings are failing to take ‘advantage’ of ...

Kenvue Inc (KVUE) stock saw a decline, ending the day at $22.04 which represents a decrease of $-0.03 or -0.14% from the prior close of $22.07. The stock opened at $22.1 and touched a low of $21.86 ...

On Thursday, Deutsche Bank (ETR:DBKGn) adjusted its stance on Kenvue Inc (NYSE:KVUE), downgrading the stock from Buy to Hold and slightly reducing the price target from $25.00 to $24.00.

Kenvue Price Performance KVUE stock opened at $22.23 on Thursday. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market ...

Be the news good or bad, our analysis of insider-transaction data from Vickers Stock Research is most actionable when the data in question is aligned. That is very much the case this week, and the ...

Kenvue Trading Down 0.3 % Kenvue stock opened at $22.74 on Wednesday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a debt-to-equity ratio of 0.66, a ...

Valued at a market cap of $43.7 billion, New Jersey-based Kenvue Inc. (KVUE) stands as the world’s largest pure-play consumer health company, a testament to over a century of trusted heritage.

These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology ...

Analyst Susan Anderson of Canaccord Genuity maintained a Buy rating on Kenvue, Inc. (KVUE – Research Report), retaining the price target of $27.00. Pick the best stocks and maximize your ...